{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T22:15:17Z","timestamp":1794694517359,"version":"4.9.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jbspin.2025.105967","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T14:00:43Z","timestamp":1757772043000},"page":"105967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The failure of IL-23 targeted therapies in axial spondyloarthritis: an unexpected observation"],"prefix":"10.1016","volume":"93","author":[{"given":"Nicolas","family":"Rosine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Miceli-Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jbspin.2025.105967_bib0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11926-016-0585-9","article-title":"The bench-to-bedside story of IL-17 and the therapeutic efficacy of its targeting in spondyloarthritis","volume":"18","author":"Smith","year":"2016","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105967_bib0155","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.23389","article-title":"Association of interleukin-23 receptor variants with ankylosing spondylitis","volume":"58","author":"Rahman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105967_bib0160","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105967_bib0165","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/sj.jid.5701140","article-title":"Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort","volume":"128","author":"Smith","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105967_bib0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3899\/jrheum.080458","article-title":"Association of interleukin 23 receptor variants with psoriatic arthritis","volume":"36","author":"Rahman","year":"2009","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.jbspin.2025.105967_bib0175","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1\u20132","key":"10.1016\/j.jbspin.2025.105967_bib0180","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol Cell Biochem"},{"issue":"7","key":"10.1016\/j.jbspin.2025.105967_bib0185","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4\u2212CD8\u2212 entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"issue":"9625","key":"10.1016\/j.jbspin.2025.105967_bib0190","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.jbspin.2025.105967_bib0195","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jbspin.2025.105967_bib0200","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/acr.22645","article-title":"Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105967_bib0205","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1136\/annrheumdis-2015-209068","article-title":"Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1\/PSUMMIT-2)","volume":"75","author":"Kavanaugh","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.jbspin.2025.105967_bib0210","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.jbspin.2025.105967_bib0215","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105967_bib0220","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","article-title":"The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling","volume":"9","author":"van Tok","year":"2018","journal-title":"Front Immunol"},{"issue":"26","key":"10.1016\/j.jbspin.2025.105967_bib0225","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105967_bib0230","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/annrheumdis-2015-209055","article-title":"Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1)","volume":"76","author":"Strand","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105967_bib0235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10163","key":"10.1016\/j.jbspin.2025.105967_bib0240","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105967_bib0245","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10370","key":"10.1016\/j.jbspin.2025.105967_bib0250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jbspin.2025.105967_bib0255","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","article-title":"Interleukin-23\u2013dependent \u03b3\/\u03b4 T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice","volume":"68","author":"Reinhardt","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.jbspin.2025.105967_bib0260","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jbspin.2025.105967_bib0265","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","article-title":"Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17\u2013secreting T cells","volume":"117","author":"Dusseaux","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jbspin.2025.105967_bib0270","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.jbspin.2025.105967_bib0275","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41467-018-07911-6","article-title":"ROR\u03b3t inhibition selectively targets IL-17 producing iNKT and \u03b3\u03b4-T cells enriched in spondyloarthritis patients","volume":"10","author":"Venken","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jbspin.2025.105967_bib0280","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/art.42090","article-title":"Characterization of blood mucosal associated invariant T (MAIT) cells in axial spondyloarthritis and of resident MAITs from control axial enthesis","volume":"74","author":"Rosine","year":"2022","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"issue":"8","key":"10.1016\/j.jbspin.2025.105967_bib0285","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/annrheumdis-2020-217309","article-title":"Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression","volume":"79","author":"Watad","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.jbspin.2025.105967_bib0290","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25001290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25001290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T20:00:48Z","timestamp":1772568048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X25001290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1297319X25001290"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105967","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The failure of IL-23 targeted therapies in axial spondyloarthritis: an unexpected observation","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105967"}}